Vera Therapeutics Inc. (NASDAQ:VERA) shares are trading lower on Tuesday, after initially spiking higher, amid increased volatility after the company announced data from the ORIGIN 3 trial.

Vera Therapeutics takes a step toward securing full Food and Drug Administration approval for its injectable kidney drug, Trutakna.

Vera Therapeutics (VERA) shares ripped higher in premarket trading on September 15 as investors reacted to landmark clinical data. The biopharmaceutical firm announced that its lead therapy TRUTAKNA (atacicept-vymj) met all primary and secondary endpoints in the final 104-week efficacy analysis of its Phase 3 ORIGIN 3 trial for primary IgA nephropathy (IgAN).

Vera Therapeutics (NASDAQ:VERA) stock is down 2% to trade at $33.34, reversing earlier gains after disclosing positive late-stage ORIGIN 3 trial results for the company's TRUTAKNA drug.